Hey, in theory, yes, this drug could work, but unless examined by the
FDA, we can't know all the side-effects (one of which could very well
be chelating too much iron, since iron is necessary for cell
metabolism). Current treatments (mentioned above) all involve
antioxidant properties, but iron chelation would be much more
effective in this disease. Current iron chelators like deferoxamine
does not target mitochondria, which is where the problems arise in
f.ataxia. But there is a new type of drug, 2-pyridylcarboxaldehyde
isonicotinoyl hydrazone (PCIH) analogues, that do target iron in the
mitochondria. The first link below is a research article on this drug
(you'll have to pay $50 for the full article, and $35 for the second
article, unless you are a suscriber... but you can read the summaries
for free). I was going to look on www.centerwatch.com (the FDA trial
drug website) for pseudan, but the site is down right now. So if
pseudan is a PCIH analogue, there is a lot of promise. But there are
still tests to be done.
http://dandini.ashley-pub.com/vl=21455475/cl=30/nw=1/rpsv/cgi-bin/linker?ini=ashley&reqidx=1354-3784(2003)L.235
http://www.springerlink.com/app/home/contribution.asp?wasp=g19taywqwj6juk8yrqau&referrer=parent&backto=issue,1,14;journal,3,19;linkingpublicationresults,1:101172,1 |